Daniel Bollag, Ph.D.

Daniel Bollag, Ph.D., brings over 25 years of R&D and executive regulatory leadership experience to Ocular Therapeutix, having most recently served as Senior Vice President of Regulatory Affairs, Pharmacovigilance & Quality at Ariad Pharmaceuticals. During his tenure at Ariad, his responsibilities included the regulatory oversight of Iclusig^® (ponatinib) and Alunbrig™ (brigatinib) from Phase 1 through accelerated regulatory approvals. Previously, Dan served as Vice President of Regulatory Affairs at Genzyme where his work included the approval of Mozobil^®. Before Genzyme, he held leadership positions at Sanofi-Aventis, Bristol-Myers Squibb and Merck & Co. Dan earned undergraduate degrees at the Pennsylvania State University and a doctorate in Biochemistry at Cornell University.